• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Efficacy of low-dose decitabine in the early relapse of malignant hematological diseases after allogeneic hematopoietic stem cell transplantation].

作者信息

Xu G F, Chen T, Liu H F, Lin S J, Gao L, Zhang C, Liu Y, Zhang X, Kong P Y

机构信息

Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China; Department of Hematology, Chongqing Fuling Central Hospital, Chongqing 408000, China.

Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2019 Aug 14;40(8):681-684. doi: 10.3760/cma.j.issn.0253-2727.2019.08.011.

DOI:10.3760/cma.j.issn.0253-2727.2019.08.011
PMID:31495137
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7342868/
Abstract
摘要

相似文献

1
[Efficacy of low-dose decitabine in the early relapse of malignant hematological diseases after allogeneic hematopoietic stem cell transplantation].低剂量地西他滨治疗异基因造血干细胞移植后恶性血液病早期复发的疗效
Zhonghua Xue Ye Xue Za Zhi. 2019 Aug 14;40(8):681-684. doi: 10.3760/cma.j.issn.0253-2727.2019.08.011.
2
Meta-analysis of decitabine pretreatment-based allogeneic hematopoietic stem cell transplantation affecting transplantation-related complications and prognosis in patients with malignant hematological disease.去甲基化药物预处理的异基因造血干细胞移植对恶性血液病患者移植相关并发症和预后影响的荟萃分析。
Cell Mol Biol (Noisy-le-grand). 2023 Dec 20;69(14):69-75. doi: 10.14715/cmb/2023.69.14.11.
3
Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia.异基因造血干细胞移植后使用地西他滨进行维持治疗以预防高危急性髓系白血病复发。
Bone Marrow Transplant. 2020 Jun;55(6):1206-1208. doi: 10.1038/s41409-019-0677-z. Epub 2019 Sep 18.
4
[The safety of decitabine as bridging pretreatment regimen before hematopoietic stem cell transplantation in pediatric hematological malignancies].[地西他滨作为儿童血液系统恶性肿瘤造血干细胞移植前桥接预处理方案的安全性]
Zhonghua Nei Ke Za Zhi. 2018 Sep 1;57(9):679-682. doi: 10.3760/cma.j.issn.0578-1426.2018.09.011.
5
Studies of decitabine with allogeneic progenitor cell transplantation.地西他滨与异基因祖细胞移植的研究。
Leukemia. 1997 Mar;11 Suppl 1:S32-4.
6
[The consensus of allogeneic hematopoietic transplantation for hematological diseases in China (2014)--indication, conditioning regimen and donor selection].《中国造血干细胞移植治疗血液系统疾病专家共识（2014版）——适应证、预处理方案及供者选择》
Zhonghua Xue Ye Xue Za Zhi. 2014 Aug;35(8):775-80. doi: 10.3760/cma.j.issn.0253-2727.2014.08.029.
7
Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.异基因干细胞移植前使用氟达拉滨和曲奥舒凡进行减低剂量预处理后的植入动力学和造血嵌合现象
Ann Hematol. 2007 Aug;86(8):583-9. doi: 10.1007/s00277-007-0294-6. Epub 2007 Apr 28.
8
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
9
Low-dose decitabine for refractory thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children: A pilot study.低剂量地西他滨治疗儿童异基因造血干细胞移植后难治性血小板减少症的一项初步研究
Int Immunopharmacol. 2023 Feb;115:109579. doi: 10.1016/j.intimp.2022.109579. Epub 2022 Dec 26.
10
[Second allogeneic hematopoietic stem cell transplant: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].[第二次异基因造血干细胞移植：法语国家骨髓移植与细胞治疗协会（SFGM-TC）指南]
Bull Cancer. 2019 Jan;106(1S):S40-S51. doi: 10.1016/j.bulcan.2018.05.018. Epub 2018 Nov 6.

本文引用的文献

1
Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.用于继发性骨髓增生异常综合征（MDS）/急性髓系白血病（AML）合并实体瘤复发儿童的表观遗传联合疗法
J Pediatr Hematol Oncol. 2017 Oct;39(7):560-564. doi: 10.1097/MPH.0000000000000868.
2
Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.在基于小剂量阿糖胞苷的化疗联合人类白细胞抗原不相合干细胞微量移植前使用地西他滨可改善新诊断的老年急性髓系白血病患者的预后。
Biol Blood Marrow Transplant. 2017 May;23(5):830-835. doi: 10.1016/j.bbmt.2017.01.085. Epub 2017 Feb 8.
3
Hypomethylating agents after allogeneic blood stem cell transplantation.异基因造血干细胞移植后的去甲基化药物
Stem Cell Investig. 2016 Nov 28;3:84. doi: 10.21037/sci.2016.11.04. eCollection 2016.
4
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.TP53与地西他滨在急性髓系白血病和骨髓增生异常综合征中的应用
N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949.
5
High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.高亲和力的FRβ特异性嵌合抗原受体T细胞可根除急性髓系白血病和正常髓系谱系细胞，且无造血干细胞毒性。
Leukemia. 2016 Jun;30(6):1355-64. doi: 10.1038/leu.2016.35. Epub 2016 Feb 22.
6
Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome.基于模型的骨髓增生异常综合征移植后地西他滨维持治疗的I期适应性试验设计
J Hematol Oncol. 2015 Oct 23;8:118. doi: 10.1186/s13045-015-0208-3.
7
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.急性髓系白血病和骨髓增生异常综合征异基因干细胞移植后使用地西他滨进行维持治疗
Biol Blood Marrow Transplant. 2015 Oct;21(10):1761-9. doi: 10.1016/j.bbmt.2015.05.026. Epub 2015 Jun 5.
8
Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).地西他滨用于异基因造血干细胞移植（allo-SCT）后复发的急性髓系白血病（AML）患者。
Ann Hematol. 2013 Apr;92(4):549-50. doi: 10.1007/s00277-012-1607-y. Epub 2012 Oct 31.
9
In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.体内给予低甲基化药物可减轻移植物抗宿主病而不牺牲移植物抗白血病。
Blood. 2010 Jul 8;116(1):129-39. doi: 10.1182/blood-2009-12-257253. Epub 2010 Apr 27.
10
The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997.世界卫生组织造血与淋巴组织肿瘤性疾病分类。临床咨询委员会会议报告，弗吉尼亚州艾丽屋，1997年11月。
Ann Oncol. 1999 Dec;10(12):1419-32. doi: 10.1023/a:1008375931236.